AIDS, published by Lippincott Williams & Wilkins, stands as a premier journal within the fields of immunology and infectious diseases, reflecting a distinguished history since its inception in 1987 and offering insights that shape contemporary research and practice. With an impressive impact factor and categorized in the Q1 quartile across critical areas including Immunology, Infectious Diseases, and Immunology and Allergy, the journal showcases high-quality, peer-reviewed articles that consistently contribute to the advancement of knowledge and innovation in the fight against AIDS and related conditions. Researchers and professionals will find its content invaluable, as it brings forth groundbreaking studies, novel therapeutic approaches, and comprehensive reviews that inform both clinical practices and public health policies. Although not an open access journal, it remains a vital resource for those committed to addressing one of the most pressing global health challenges of our time.

HIV Research & Clinical Practice, published by Taylor & Francis Ltd, is an essential open-access journal dedicated to advancing the knowledge and understanding of HIV-related research and clinical practices. With an ISSN of 2578-7489 and E-ISSN 2578-7470, this acclaimed journal is committed to disseminating cutting-edge studies and innovative treatment strategies within the infectious diseases and pharmacology fields, achieving a commendable Q2 ranking in both categories as of 2023. The journal's scope encompasses a broad range of topics from basic science to clinical application, providing a vital platform for researchers, clinicians, and students to exchange insights and foster collaboration. As an open-access publication since 2022, it ensures that high-quality research is accessible to a global audience, encouraging a greater understanding of HIV and its implications for public health. With its base in the United Kingdom and a convergence period from 2019 to 2024, HIV Research & Clinical Practice stands at the forefront of the fight against HIV/AIDS, making significant contributions to the clinical community and beyond.

The Indian Journal of Sexually Transmitted Diseases and AIDS, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, serves as a vital platform for disseminating research and knowledge in the fields of sexually transmitted infections and HIV/AIDS management. With ISSN 2589-0557 and E-ISSN 2589-0565, this journal aims to bridge the gap in public health and clinical research by providing peer-reviewed articles that cover a range of topics from epidemiology to therapeutic advancements. Despite its status with an impact factor in the lower quartiles across relevant categories, including Q3 in Dermatology, Q4 in Infectious Diseases, and Q4 in Public Health, it holds potential for growth and greater visibility within the academic community. The journal's scope spans critical insights and innovative approaches in managing sexually transmitted diseases, and it is committed to fostering scholarly discourse among its readership consisting of researchers, health professionals, and students alike. As it converges from 2018 to 2024, the Indian Journal of Sexually Transmitted Diseases and AIDS continues to underscore the importance of addressing pressing health issues in India and beyond, while offering an accessible resource for those dedicated to this vital field.

The Lancet HIV, published by Elsevier Inc in the United Kingdom, stands at the forefront of HIV research and public health, providing a vital platform for the dissemination of innovative findings and critical knowledge in the fields of epidemiology, immunology, infectious diseases, and virology. With its prestigious Q1 rankings in the aforementioned categories for 2023, the journal is recognized for its significant contribution to advancing understanding and addressing challenges posed by HIV globally. Its impressive standing, including a Scopus ranking in the 94th percentile for multiple categories, underscores its impact within the research community. The Lancet HIV publishes rigorously peer-reviewed research articles, reviews, and opinion pieces, ensuring that all stakeholders—researchers, practitioners, and policymakers—are engaged with up-to-date, evidence-based perspectives. Researchers and students alike will find this journal an invaluable resource for enhancing their knowledge and contributing to the ongoing discourse surrounding HIV treatment and prevention.

JAIDS - Journal of Acquired Immune Deficiency Syndromes, is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamics of HIV/AIDS and its broader implications in the fields of infectious diseases and pharmacology. With an esteemed impact factor that places it in the prestigious Q1 category for both Infectious Diseases and Pharmacology (medical) as of 2023, this journal aims to provide a platform for groundbreaking research, clinical findings, and innovative therapies relevant to the management and prevention of HIV/AIDS. The journal's rigorous editorial standards and commitment to advancing knowledge make it an essential resource for researchers, healthcare professionals, and students invested in the global response to AIDS. Although the journal does not currently offer open access options, it remains instrumental in disseminating high-quality research that shapes clinical practices and policy developments in the field.

HIV Medicine is a prestigious journal published by Wiley that stands at the forefront of research in the fields of health policy, infectious diseases, and pharmacology, with a commendable impact factor reflected in its Q1 rankings for 2023. Established in 1999 and set to converge its expertise through 2024, this journal plays a critical role in advancing the understanding and treatment of HIV and related health challenges. It is esteemed for its rigorous peer-review process and its contributions to both clinical and policy-oriented discussions surrounding HIV medicine. With a broad international readership, it serves as a vital resource for researchers, healthcare professionals, and students committed to fighting the global HIV epidemic. Although not open access, its vital insights are indispensable for anyone involved in infectious disease research and healthcare policy. Articles published in HIV Medicine shape global health strategies and influence the future of HIV research, making it a must-read for those dedicated to this crucial field.

Global Health & Medicine is a leading journal published by the National Center for Global Health and Medicine (NCGM), dedicated to advancing the fields of public health, epidemiology, and medical research. With the increasing importance of global health issues, this journal serves as a vital resource for researchers, healthcare professionals, and students alike, providing a platform for the dissemination of groundbreaking studies and innovative solutions to health challenges worldwide. Although specific metrics such as HIndex and category quartiles are yet to be established, the journal's commitment to open access ensures that vital information is accessible to a global audience, promoting knowledge sharing across borders. The journal's ISSN and E-ISSN number, 2434-9186 and 2434-9194 respectively, represent its dedication to maintaining high standards in academic publishing. As global health continues to evolve, Global Health & Medicine stands at the forefront, addressing the complexities of health systems, disease prevention, and health promotion essential for fostering a healthier world.

SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE, published by AOSIS, stands as a vital resource in the field of Infectious Diseases, particularly focusing on HIV medicine. With an ISSN of 1608-9693 and E-ISSN 2078-6751, this Open Access journal has been dedicated to disseminating cutting-edge research since 2001, ensuring that findings are accessible to a global audience of researchers, healthcare professionals, and students. Operating out of South Africa, the journal has earned a position in the Q3 quartile for Infectious Diseases, reflecting its commitment to advancing the understanding and treatment of HIV-related issues. Its Scopus ranking, presently at #207 out of 344, further emphasizes its scholarly influence, positioning it as an essential publication within the medical community. The journal aims to foster collaboration and innovation in HIV research and practice, bridging gaps between theory and real-world application to improve health outcomes in southern Africa and beyond.

INTERNATIONAL JOURNAL OF STD & AIDS is a prominent publication dedicated to advancing the understanding and treatment of sexually transmitted diseases and HIV/AIDS. Published by SAGE Publications Ltd, this esteemed journal has been contributing to the medical community since 1990, with a convergence of studies spanning to 2024. With its ISSN 0956-4624 and E-ISSN 1758-1052, the journal is recognized for its rigorous peer-reviewed research and has successfully positioned itself in the second quartile (Q2) of Dermatology and Public Health, alongside notable rankings in Infectious Diseases and Pharmacology. Currently based in the United Kingdom, this journal serves as a crucial resource for researchers, healthcare professionals, and students, providing a platform for innovative studies and critical reviews that address global health challenges. Although it does not offer Open Access, the journal continues to maintain its reputation as a vital reference point for those invested in the fields of dermatology, public health, and infectious diseases.

AIDS RESEARCH AND HUMAN RETROVIRUSES, published by Mary Ann Liebert, Inc., is a pivotal journal dedicated to advancing the field of HIV research and the broader spectrum of human retroviruses. With an ISSN of 0889-2229 and an E-ISSN of 1931-8405, this journal has been in continuous publication since 1987 and is respected in the academic community for its rigorous peer-reviewed articles. As a Q3 ranked journal in Immunology, Infectious Diseases, and Virology as of 2023, it plays a crucial role in disseminating cutting-edge research, theoretical advancements, and clinical insights that contribute significantly to the understanding and treatment of HIV and related disorders. The journal's objective is to foster collaboration among researchers, healthcare professionals, and educators by providing a platform for the exchange of innovative ideas and findings. Although not an open-access journal, its compelling content ensures that it remains a primary resource for those in the academic and medical communities tackling the challenges posed by retroviral infections. With a commitment to excellence and relevance, AIDS RESEARCH AND HUMAN RETROVIRUSES continues to shape the future of research in this critical area.